Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-02-22
2005-02-22
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C424S193100, C424S194100, C435S975000, C436S506000, C436S069000, C514S012200, C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C530S324000, C530S315000, C530S326000, C530S327000, C530S328000, C530S329000, C530S413000
Reexamination Certificate
active
06858210
ABSTRACT:
The present invention provides domain 1 β2GPI polypeptides, polynucleotides encoding these polypeptides, mimetics of these polypeptides, and methods using domain 1 β2GPI polypeptides and mimetics. Domain 1 of β2GPI has been shown to bind to anti-cardiolipin (β2GPI-dependent antiphospholipid) antibodies, which are associated with several pathologies, such as thrombosis and fetal loss. The domain 1 β2GPI polypeptides may be used to detect β2GPI-dependent antiphospholipid antibodies in a sample. The invention further provides methods of inducing tolerance using these domain 1 β2GPI polypeptides.
REFERENCES:
patent: 4191668 (1980-03-01), Katz
patent: 4650675 (1987-03-01), Borel et al.
patent: 4751181 (1988-06-01), Keene
patent: 5126131 (1992-06-01), Dintzis et al.
patent: 5162515 (1992-11-01), Conrad et al.
patent: 5268454 (1993-12-01), Barstad et al.
patent: 5276013 (1994-01-01), Conrad et al.
patent: 5344758 (1994-09-01), Krilis et al.
patent: 5370871 (1994-12-01), Dintzis et al.
patent: 5472883 (1995-12-01), Matsuura et al.
patent: 5498538 (1996-03-01), Kay et al.
patent: 5506110 (1996-04-01), Matsuura et al.
patent: 5552391 (1996-09-01), Coutts et al.
patent: 5606047 (1997-02-01), Coutts et al.
patent: 5633395 (1997-05-01), Coutts et al.
patent: 5780319 (1998-07-01), Maxfield Wilson et al.
patent: 5859213 (1999-01-01), Stefas et al.
patent: 5874409 (1999-02-01), Victoria et al.
patent: 5998223 (1999-12-01), Matsuura et al.
patent: 6022544 (2000-02-01), Dintzis et al.
patent: 6060056 (2000-05-01), Coutts et al.
patent: 6207160 (2001-03-01), Victoria et al.
patent: 20010051351 (2001-12-01), Racis
patent: 20020025321 (2002-02-01), Shoenfeld et al.
patent: 20020110535 (2002-08-01), Jones
patent: 0 438 259 (1991-07-01), None
patent: 0 442 724 (1991-08-01), None
patent: 0 442 724 (1991-08-01), None
patent: 0 498 658 (1992-08-01), None
patent: 0 498 658 (1992-08-01), None
patent: 0 498 658 (1992-08-01), None
patent: 0 642 798 (1995-03-01), None
patent: 0 730 155 (1996-09-01), None
patent: 0 821 003 (1998-01-01), None
patent: WO 8604093 (1986-07-01), None
patent: WO 8700056 (1987-01-01), None
patent: WO 8809810 (1988-12-01), None
patent: WO 8909628 (1989-10-01), None
patent: WO 9110426 (1991-07-01), None
patent: WO 9115772 (1991-10-01), None
patent: WO 9211029 (1992-07-01), None
patent: WO 9213558 (1992-08-01), None
patent: WO 9302093 (1993-02-01), None
patent: WO 9507073 (1995-03-01), None
patent: WO 9514231 (1995-05-01), None
patent: WO 9514231 (1995-05-01), None
patent: WO 9604006 (1996-02-01), None
patent: WO 9604006 (1996-02-01), None
patent: WO 9640197 (1996-12-01), None
patent: WO 9746251 (1997-12-01), None
patent: WO 9812133 (1998-05-01), None
patent: WO 9821233 (1998-05-01), None
patent: WO 9947925 (1999-09-01), None
patent: WO 9964595 (1999-12-01), None
patent: WO 0001729 (2000-01-01), None
patent: WO 0001729 (2000-01-01), None
patent: WO 0020019 (2000-04-01), None
patent: WO 0034231 (2000-06-01), None
patent: WO 0075105 (2000-12-01), None
patent: WO 0118541 (2001-03-01), None
patent: WO 0141813 (2001-06-01), None
patent: WO 0179449 (2001-10-01), None
patent: WO 0188088 (2001-11-01), None
patent: WO 0227315 (2002-04-01), None
patent: WO 0066715 (2002-11-01), None
Palkeyeua et al (USPTO Translation).*
Cruse et al pp. 102-103 Illustrated Dictionary of Immunology, 1995 CRC Press.*
Abaza et al. J. of Protein Chemistry, 11(5):433-444, 1992.*
Matsuura et al, J. of Immunology, 148:3885-91, 1992.*
Sequence Search—US-09-328-199-6-open.1 spt—US-09-328-199-8-open.1spt by PTO on GenCoreVersion 4.5 Compugen '93, Dec, 20, 2000.*
Arvieux et al. (1991). “Measurement of anti-phospholipid antibodies by ELISA using β2-glycoprotein I as an antigen”J. Immunol. Methods143:223-229.
Ausubel et al., eds. (1987). Current Protocols in Molecular Biology. Table of contents enclosed herewith.
Bakimer et al. (1992). “Induction of Primary Antiphosholipid Syndrome in Mice by Immunization with a Human Monoclonal Anticardiolipin Antibody (H-3)”J. Clin. Invest.89:1558-1563.
Balaram. (1992). “The design and construction of synthetic protein mimics”Pure&Appl. Chem.64:1061-1066.
Barbas et al. (1991). “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site”Proc. Natl. Acad. Sci. USA88:7978-7982.
Barlow et al. (1991). “Secondary Structure of a Complement Control Protein Module by Two-Dimensional1H NMR”Biochem.30:997-1004.
Blank et al. (1991). “Induction of anti-phospholipid syndrome in naive mice wtih mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies”Proc. Natl. Acad. Sci.88:3069-3073.
Borel et al. (1990). “A novel technique to link either proteins or peptides to gammaglobulin to construct tolerogens”Immunol. Methods126:159-168.
Borel et al. (1995). “Food Allergens Transformed into Tolerogens”Int. Arch. Allergy Immunol.107:264-267.
Borel et al. (1996). “Parenteral and Oral Administration of tolerogens: Protein-IgG Conjugates”Ann. N.Y. Acad. Sci.778:80-87.
Burgess et al. (1995).“Comparison of the Effects of (2S, 3S)-2,3-Methanomethionine, (2R,3R)-2,3-Methanomethionine, and (2R,3R)-2,3-Methanophenylalainie on the Confrontations of Small Peptides”J. Am. Chem. Soc.117:3808-3819.
Coligan et al., eds. (1991)Current Protocols in Immunology, Table of contents enclosed herewith.
Dumas et al. (1995). “Induction of tolerance by administration of hapten-immunoglobulin conjugates is associated with decreased IL-2 and IL-4 production”Arch. Dematol. Res.287:123-128.
Freshney, ed. (1987).Animal Cell Culture a practical approach.Table of contents enclosed herewith.
Gacesa et al. (1994).Vectors, Essential Data.John Wiley & Sons.
Gait, ed. (1984).Oligonucleotide Synthesis, a practical approach.Table of contents enclosed herewith.
Galli et al. (1990). “Anticardiolipin antibodies (ACAA) directed not to cardiolipin but to a plasma protein cofactor”Lancet335:1544-1547.
George et al. (1998). “Target recognition of β2-Glycoprotein I (β2GPI)-Dependent Anticardiolipin Antibodies: Evidence for Involvement of the Fourth Domain of β2GPI in Antibody Binding”J. Immunol.160:3917-3923.
Gharavi et al. (1987). “Anticardiolipin antibodies: isotype distribution and phospholipid specificity”Ann. Rheum. Dis.46m:1-6.
Harris et al. (1983). “Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus”Lancet2:1211-1214.
Harris et al. eds. (1991).Phospholipid-Binding Antibodies.CRC Press: Boca Raton, FL. Table of Contents Only.
Hinds et al. (1991). “Synthesis Conformational Properties, and Antibody Recognition of Peptides Containing β-Turn Mimitecs based on α-Alkylproline Derivatives”Med. Chem.34:1777-1789.
Hruby et al. (1990). “Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations”Biochem. J.268:249-262.
Hruby et al. (1994). “Design of Novel Synthetic Peptides Including Cyclic Conformationally and Topographically Constrained Analogs”Methods in Mol. Biol.35:201-240.
Hunt et al. (1993). “Identification of a region of β2-glycoprotein I critical for Lipid binding and anti-cardiolipin antibody cofactor activity”Proc. Natl. Acad. Sci. USA90:2141-2145.
Hunt et al. (1994). “The Fifth Domain of β2-Glycoprotein I Contains a Phospholipid Binding Site (Cys281-Cys288) and a Region Recognized by Anticardiolipin Antibodies”J. Immunol.152(2):653-659.
Ichinose et al. (1990) “Structure of transglutaminases”J. Biol. Chem.265(23):13411-13414.
Igarashi et al. (1996). “Human β2-Glycoprotein I as an Anticardiolipin Cofactor Determined Using Deleted Mutants Expressed by a Baculovirus System”Blood87:3262-3270.
Iverson et al. (1998). “Anti-β2 glycoprotein I
Iverson Gilbert M.
Jones David S.
Linnik Matthew D.
Marquis David M.
Victoria Edward J.
La Jolla Pharmaceutical Co.
Morrison & Foerster / LLP
Saunders David
LandOfFree
Therapeutic and diagnostic domain 1 β2GPI polypeptides... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic and diagnostic domain 1 β2GPI polypeptides..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and diagnostic domain 1 β2GPI polypeptides... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3504075